all report title image

Autism Spectrum Disorder Therapeutics Market, By Drug Type (Aripiprazole, Risperidone, Melatonin, CM-AT, Bumetanide, and Balovaptan), By Age Group (Child and Adult), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : 29 Jan, 2026
  • Code : CMI2643
  • Pages :151
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Autism, scientifically referred as Autism Spectrum Disorder Therapeutics (ASD) is a complex neurological disorder that is characterized by symptoms including challenges with social skills, repetitive behaviours, as well as issues with speech and non-verbal communication. Major companies operating in the ASD therapeutics market are focusing on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure.

Market Dynamics

Increasing prevalence of ASD worldwide is expected to boost the Autism Spectrum Disorder Therapeutics (ASD) therapeutics market growth. For instance, according to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Moreover, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders.

However, stringent regulations and continuous watch employed by governing authorities for product approval and marketing of medicines can act as a potential hindrance for growth of the autism spectrum disorder therapeutics market. For instance, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism.

Key features of the study

  • This report provides in-depth analysis of the autism spectrum disorder therapeutics market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global autism spectrum disorder therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global autism spectrum disorder therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Autism Spectrum Disorder Therapeutics market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

  • Drug Type Insights (Revenue, USD Mn, 2026 - 2033)
    • Aripiprazole
    • Risperidone
    • Melatonin
    • CM-AT
    • Bumetanide
    • Balovaptan
  • Age Group Insights (Revenue, USD Mn, 2026 - 2033)
    • Child
    • Adult
  • Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Mn, 2026 - 2033)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • North Africa
      • Central Africa
      • South Africa
  • Key Players Insights
    • F. Hoffmann-La Roche AG
    • Neurim Pharmaceuticals, Inc.
    • Yamo Pharmaceuticals LLC
    • Servier Laboratories Ltd.
    • Otsuka Holdings Co. Ltd.
    • Curemark LLC
    • Oryzon Genomics S.A.
    • GW Pharmaceuticals Plc.
    • Teva Pharmaceutical Industries Ltd.
    • Zynerba Pharmaceuticals Inc.
    • STALICLA SA
    • Novartis AG
    • Pfizer, Inc.
    • Bristol Myers Squibb

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Global Autism Spectrum Disorder Therapeutics Market, By Drug Type
      • Global Autism Spectrum Disorder Therapeutics Market, By Age Group
      • Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel
      • Global Autism Spectrum Disorder Therapeutics Market, By Region
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
    • Impact Analysis
    • Key Highlights
    • Regulatory Scenario
    • Product Launches/Approvals
    • PEST Analysis
    • PORTER’s Analysis
    • Market Opportunities
    • Regulatory Scenario
    • Key Developments
    • Industry Trend
  4. Global Autism Spectrum Disorder Therapeutics Market, By Drug Type, 2020-2033, (USD Mn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Aripiprazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
    • Risperidone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
    • Melatonin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
    • CM-AT
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
    • Bumetanide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
    • Balovaptan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  5. Global Autism Spectrum Disorder Therapeutics Market, By Age Group, 2020-2033, (USD Mn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Child
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
    • Adult
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  6. Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel, 2020-2033, (USD Mn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  7. Global Autism Spectrum Disorder Therapeutics Market, By Region, 2020 - 2033, Value (USD Mn)
    • Introduction
      • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
      • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Value (USD Mn)
      • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
        • Brazil
        • Argentina
        • Mexico
        • Rest of Latin America
    • Europe
      • Introduction
      • Value (USD Mn)
      • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
        • Germany
        • U.K.
        • Spain
        • France
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Value (USD Mn)
      • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Value (USD Mn)
      • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Value (USD Mn)
      • Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
        • South Africa
        • North Africa
        • Central Africa
  8. Competitive Landscape
    • F. Hoffmann-La Roche AG
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Neurim Pharmaceuticals, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Yamo Pharmaceuticals LLC
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Servier Laboratories Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Otsuka Holdings Co. Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Curemark LLC
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Oryzon Genomics S.A.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • GW Pharmaceuticals Plc.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Zynerba Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • STALICLA SA
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Novartis AG
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Pfizer, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Bristol Myers Squibb
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
  9. Analyst Recommendations
    • Wheel of Fortune
    • Analyst View
    • Coherent Opportunity Map
  10. References and Research Methodology
    • References
    • Research Methodology
    • About us
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.